Author + information
In the article by Skyler JS, Bergenstal R, Bonow RO, et al., “Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association,” which published ahead of print on December 17, 2008, and appeared in the January 20, 2009, issue of the journal (J Am Coll Cardiol 2009;53:298–304), a correction should be made to Richard Bergenstal's disclosure of potential financial dualities of interest information.
The second full paragraph in the right-hand column on p. 303 should be replaced with the following information:
R.B. participates in clinical research or has served on a scientific advisory board for Amylin, Merck, Pfizer, ResMed, Valeritas, Eli Lilly, Novo Nordisk, sanofi-aventis, MannKind, Intuity, Roche, LifeScan, Abbott, Bayer, and Medtronic. R.B. receives no personal compensation for these activities; all contracts are through the nonprofit Park Nicollet Institute. R.B. holds stock in Merck through a family inheritance and is an officer within the American Diabetes Association.
- American College of Cardiology Foundation